Syngene Makes Strong Debut On Indian Bourses
This article was originally published in Scrip
Executive Summary
Syngene International has made a strong debut on Indian bourses listing at INR295 ($4.6) and closing higher, even as the overall market declined in the country. Syngene is the research services arm of Biocon.
You may also be interested in...
Biocon’s Malaysia Insulin Plant Wins EU Clearance, Company Is Open To PE Investment
Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.
M&A Trends: The Growing Indian Appetite
A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.